Compare NSSC & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | DAWN |
|---|---|---|
| Founded | 1969 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | NSSC | DAWN |
|---|---|---|
| Price | $42.63 | $11.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $48.17 | $27.56 |
| AVG Volume (30 Days) | 478.9K | ★ 3.1M |
| Earning Date | 02-02-2026 | 02-27-2026 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | ★ 0.75 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $192,025,000.00 | $133,672,000.00 |
| Revenue This Year | $13.32 | $18.27 |
| Revenue Next Year | $9.84 | $48.39 |
| P/E Ratio | $32.59 | ★ N/A |
| Revenue Growth | 2.94 | ★ 31.11 |
| 52 Week Low | $19.00 | $5.64 |
| 52 Week High | $48.12 | $13.20 |
| Indicator | NSSC | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 54.87 |
| Support Level | $41.71 | $10.30 |
| Resistance Level | $44.27 | $11.84 |
| Average True Range (ATR) | 1.68 | 0.79 |
| MACD | 0.54 | -0.10 |
| Stochastic Oscillator | 73.59 | 39.44 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.